ATEC, FOSL, CRWD Lead Post-EPS-Revision Rally: ATEC +18.3%
Five stocks screened by our EPS revision tracker have delivered outsized gains since detection, led by Alphatec Holdings (ATEC) at +18.3%, Fossil Group (FOSL) at +17.6%, and CrowdStrike (CRWD) at +16.7%. FOSL's forward EPS growth estimate was revised from 111.5% to 776.2%, while CYPH saw a 2,560-percentage-point revision to 2,900%. No direct earnings news was found for most names, suggesting the market is repricing off estimate momentum alone.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| ATEC | Healthcare | 2026-09-09 | N/A | +18.3% |
| FOSL | Consumer Cyclical | 2026-09-10 | +664.7pp | +17.6% |
| CRWD | Technology | 2026-09-13 | N/A | +16.7% |
| CYPH | Healthcare | 2026-09-10 | +2560.0pp | +15.4% |
| TWST | Healthcare | 2026-09-09 | +1.5pp | +14.2% |
Why did ATEC stock jump in September 2026?
ATEC jumped 18.3% (from $8.98 to $10.62) after screening on September 9, 2026, with a next-year EPS growth estimate of 86.6%.
No earnings-specific news hit the tape during the window, so the move reflects the market slowly repricing the spinal-surgery device maker's profit trajectory. Alphatec has been converting revenue growth into operating leverage, and the 86.6% forward EPS growth estimate suggests analysts see that trend accelerating. The screener caught the revision early, and the price confirmation followed within a week.
ATEC EPS revision history → · Screener snapshot from 2026-09-09 →
FAQ: ATEC
Why did ATEC stock jump in September 2026?
ATEC rose 18.3% from $8.98 to $10.62 after appearing on our EPS revision screener on September 9, 2026 with an 86.6% next-year EPS growth estimate. No single news catalyst was identified, pointing to estimate-driven repricing.
What is ATEC's EPS growth estimate?
ATEC's forward next-year EPS growth estimate stands at 86.6% as of the September 2026 screening. The revision reflects analyst expectations for accelerating profitability at the spinal device maker.
Is ATEC a buy after the 18% rally?
The 18.3% move already prices in some of the 86.6% EPS growth estimate, but if the revision holds, the stock could still be underappreciated by the broader market. Traders should watch for follow-through volume and any Q3 guidance updates.
Why did FOSL stock jump in September 2026?
FOSL surged 17.6% to $5.28 from $4.49 after its next-year EPS growth estimate was revised from 111.5% to 776.2% — a 664.7-percentage-point jump — between September 10 and September 16, 2026.
The magnitude of that revision implies a dramatic reset in expectations for the watch and accessories maker, likely driven by cost-cutting, licensing renegotiations, or turnaround execution. No earnings-related news crossed the wire during the window, making this a pure estimate-momentum move. The market's +17.6% confirmation shows traders are starting to believe the higher-profitability narrative even without a formal press release.
FOSL EPS revision history → · Screener snapshot from 2026-09-10 →
FAQ: FOSL
Why did FOSL stock jump in September 2026?
FOSL jumped 17.6% to $5.28 from $4.49 after its forward EPS growth estimate was revised from 111.5% to 776.2% on September 10, 2026. The 664.7-percentage-point revision reflects a major reset in analyst profitability assumptions.
What caused FOSL's 776.2% EPS growth estimate?
The revision implies analysts are modeling a sharp turnaround in Fossil's earnings, likely from cost cuts, licensing deals, or restructuring. No earnings press release was identified in the window, so the revision stems from analyst model updates.
Is FOSL a buy after the rally?
FOSL remains a low-priced, high-volatility name, so the 17.6% gain should be weighed against execution risk. The 776.2% EPS growth estimate is only meaningful if management delivers on the turnaround.
Why did CRWD stock jump in September 2026?
CRWD climbed 16.7% to $241.29 from $206.74 after being detected by our screener on September 13, 2026 with a 27.5% next-year EPS growth estimate.
The move was reinforced by an AI-slowdown debate that broke into the open on September 14, where CrowdStrike CEO George Kurtz joined Nvidia and Broadcom in dismissing a development pullback. As AI models proliferate, cybersecurity demand rises, and that linkage gave traders a sector-wide reason to bid up CRWD. The 27.5% growth estimate is steady rather than explosive, but the price action confirms the market is pricing in durable demand.
CRWD EPS revision history → · Screener snapshot from 2026-09-13 →
FAQ: CRWD
Why did CRWD stock jump in September 2026?
CRWD rose 16.7% from $206.74 to $241.29 after screening on September 13, 2026 with a 27.5% next-year EPS growth estimate, then got a lift from the September 14 AI-slowdown debate where CrowdStrike's CEO dismissed a development pullback.
What is CRWD's EPS growth estimate?
CRWD's forward next-year EPS growth estimate is 27.5% as of the September 2026 screening. That reflects steady, durable earnings growth rather than an explosive revision.
Is CRWD a buy after the AI debate?
The AI debate reinforced CrowdStrike's positioning as a cybersecurity beneficiary of AI proliferation, but the stock is already up 16.7%. Investors should weigh that move against the 27.5% EPS growth estimate and valuation.
Why did CYPH stock jump in September 2026?
CYPH rose 15.4% to $2.54 from $2.20 after its next-year EPS growth estimate was revised from 340% to 2,900% — a 2,560-percentage-point increase — between September 10 and September 16, 2026.
That revision implies analysts now expect a massive jump in profitability for the healthcare name, even though no earnings-specific news was identified in the window. The magnitude suggests a low base effect or a major shift in the company's outlook. The market's +15.4% confirmation shows traders are willing to chase the estimate momentum despite the absence of a formal catalyst.
CYPH EPS revision history → · Screener snapshot from 2026-09-10 →
FAQ: CYPH
Why did CYPH stock jump in September 2026?
CYPH jumped 15.4% to $2.54 from $2.20 after its next-year EPS growth estimate was revised from 340% to 2,900% on September 10, 2026. That 2,560-percentage-point revision drove the estimate-momentum move.
What is CYPH's EPS growth estimate?
CYPH's forward next-year EPS growth estimate was revised to 2,900%, up from 340%, as of September 2026. The revision reflects a dramatic change in analyst profitability assumptions.
Is CYPH a buy after the rally?
CYPH is a low-priced stock with an outsized EPS growth estimate, so the 15.4% rally should be approached with caution. The 2,900% estimate is only as good as the underlying earnings delivery.
Why did TWST stock jump in September 2026?
TWST gained 14.2% to $143.31 from $125.52 after screening on September 9, 2026, with its next-year EPS growth estimate revised from 35.1% to 36.6%.
That 1.5-percentage-point revision is modest, but for a high-price, high-multiple synthetic biology name, even a small bump can move the stock sharply. No earnings-related news was found in the window, so the move likely reflects sector momentum in healthcare and continued enthusiasm for Twist's DNA synthesis platform. The screener flagged the revision early, and the +14.2% gain shows the market took the signal seriously.
TWST EPS revision history → · Screener snapshot from 2026-09-09 →
FAQ: TWST
Why did TWST stock jump in September 2026?
TWST rose 14.2% from $125.52 to $143.31 after screening on September 9, 2026 with its next-year EPS growth estimate revised from 35.1% to 36.6%. The modest revision was enough to trigger a double-digit move in the high-multiple name.
What is TWST's EPS growth estimate?
TWST's forward next-year EPS growth estimate is 36.6%, up from 35.1%, as of the September 2026 screening. The 1.5-percentage-point revision reflects slightly improved analyst sentiment.
Is TWST a buy after the 14% rally?
The 14.2% gain already reflects the improved estimate, so TWST's upside depends on whether sector momentum in synthetic biology continues. The 36.6% EPS growth estimate supports a constructive but not aggressive stance.
Today's top performers — ATEC, FOSL, CRWD, CYPH, and TWST — signal that estimate revisions are a powerful short-term catalyst, especially when the market lacks other news. The breadth across healthcare, consumer cyclical, and technology suggests investors are hunting for earnings momentum rather than chasing a single sector theme.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →